ADVAIR DISKUS® 500/50
Sponsors
Respirent Pharmaceuticals Co Ltd.
Conditions
Bioequivalence
Phase 1
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
CompletedNCT04546256
Start: 2020-09-01End: 2020-12-31Updated: 2021-03-09
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
CompletedNCT04564456
Start: 2020-09-22End: 2020-12-31Updated: 2021-01-20
Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
NCT06025214
Start: 2023-08-22End: 2023-10-31Target: 34Updated: 2023-09-06